Targets › MTB
1 program from 1 company in 3 trials: 3 Phase 2; Infectious disease.
Open in Phaseline: the race on MTB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bharat Biotech International | MTBVAC (BBV169) Live attenuated Mycobacterium tuberculosis vaccine | MTB | Phase 2 | Tuberculosis (TB); HIV I Infection | – |
Tuberculosis (TB) (2) HIV I Infection (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.